ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)
journal contribution
posted on 2023-06-08, 18:31authored byF Cardoso, A Costa, L Norton, E Senkus, M Aapro, F André, C H Barrios, J Bergh, L Biganzoli, K L Blackwell, M J Cardoso, T Cufer, N El Saghir, Lesley FallowfieldLesley Fallowfield, D Fenech, P Francis, K Gelmon, S H Giordano, J Gligorov, A Goldhirsch, N Harbeck, N Houssami, C Hudis, B Kaufman, I Krop, S Kyriakides, U N Lin, M Mayer, S D Merjaver, E B Nordstrom, O Pagani, A Partridge, F Penault-Llorca, M J Piccart, H Rugo, G Sledge, C Thomssen, L Van't Veer, D Vorobiof, C Vrieling, N West, B Xu, E Winer
Advanced Breast Cancer (ABC) is a treatable but still generally incurable disease. The goals of care are to optimize both length and quality of life. Due to continuous research, several advances have been made, particularly for the HER-2-positive and for Luminal-like subtypes. Notwithstanding these advances, median overall survival of patients with ABC is still only 2–3 years, although the range is wide [1–5], and survival may be longer for patients treated in specialized institutions [6]. Implementation of current knowledge is highly variable among countries and within each country.